Article Information
History
- September 19, 2020.
Article Versions
- You are currently viewing Version 1 of this article (September 19, 2020 - 22:55).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Andrea Loreto*,1,6,
- Carlo Angeletti2,6,
- Jonathan Gilley1,
- Peter Arthur-Farraj1,
- Elisa Merlini1,
- Adolfo Amici2,
- Laura M. Desrochers3,4,
- Qi Wang3,5,
- Giuseppe Orsomando*,2,7 and
- Michael P. Coleman*,1,7
- 1John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Forvie Site, Robinson Way, CB2 0PY, Cambridge, UK
- 2Department of Clinical Sciences (DISCO), Section of Biochemistry, Polytechnic University of Marche, Via Ranieri 67, Ancona 60131, Italy
- 3Neuroscience, BioPharmaceuticals R&D, AstraZeneca, Waltham, MA, USA
- 4Vertex Pharmaceuticals, 50 Northern Ave, Boston, MA 02210, USA
- 5Kymera Therapeutics, 200 Arsenal Yards Blvd, Watertown, MA 02472, USA
- ↵*Corresponding author: Prof Michael Coleman Email: mc469{at}cam.ac.uk, Dr Andrea Loreto Email: al850{at}cam.ac.uk, Dr Giuseppe Orsomando Email: g.orsomando{at}staff.univpm.it
↵6,7 Equal contribution